Radiopharm Theranostics Aktie - RADX

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

6,41

Gebot

6,30

Fragen

11,11

Volumen

114.477

6,04 Tagesbereich 7,99

0,00 52-Wochen-Bereich 0,00

Handelsende

6,53

Handelsbeginn

6,38

Letzte Trade

6.3001

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

US$ 780.923

VWAP

6,8217

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 millionPlacement at A$0.060 per...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

RADX - Frequently Asked Questions (FAQ)

What is the current Radiopharm Theranostics share price?

The current share price of Radiopharm Theranostics is US$ 6,41

What is the 1 year trading range for Radiopharm Theranostics share price?

Radiopharm Theranostics has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
ABLVAble View Global Inc	US$ 1,73 (137,18%)	5,14M
SUNESUNation Energy Inc	US$ 0,402999 (127,55%)	482,05M
BTOGBit Origin Ltd	US$ 0,6117 (118,46%)	622,67M
DWTXDogwood Therapeutics Inc	US$ 6,63 (49,66%)	25,92M
KZIAKazia Therapeutics Ltd	US$ 1,1899 (40,80%)	4,5M
ALBTAvalon GloboCare Corporation	US$ 6,96 (-36,15%)	570,43k
SCNXScienture Holdings Inc	US$ 1,55 (-35,68%)	1,54M
ACXPAcurx Pharmaceuticals Inc	US$ 0,4572 (-29,88%)	1,13M
RETOReTo Eco Solutions Inc	US$ 5,42 (-27,73%)	108k
OCTOEightco Holdings Inc	US$ 1,08 (-27,03%)	332,1k
BTOGBit Origin Ltd	US$ 0,6117 (118,46%)	618,03M
SUNESUNation Energy Inc	US$ 0,402999 (127,55%)	476,73M
NVDANVIDIA Corporation	US$ 112,69 (1,92%)	333,91M
ICONIcon Energy Corporation	US$ 0,169898 (17,17%)	140,23M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 10,675 (-0,70%)	140,05M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Radiopharm Theranostics Ltd (RADX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

RADX Neueste Nachrichten

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RADX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Radiopharm Theranostics Ltd (RADX) Börsenkurse

Radiopharm Theranostics Ltd (RADX)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

RADX Neueste Nachrichten

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Lantheus Increases to 12.16% shareholding in Radiopharm with US$5m (A$8m) Placement

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RADX - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR